Ziprasidone (hydrochloride)
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Ziprasidone (hydrochloride)
Description :
Ziprasidone (CP-88059) hydrochloride is an orally active combined 5-HT and dopamine receptor antagonist[1]. Ziprasidone hydrochloride has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM) [1].Product Name Alternative :
CP-88059 hydrochlorideUNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
5-HT Receptor; Dopamine ReceptorType :
Reference compoundRelated Pathways :
GPCR/G Protein; Neuronal SignalingApplications :
Neuroscience-NeuromodulationField of Research :
Neurological DiseaseAssay Protocol :
https://www.medchemexpress.com/ziprasidone-hydrochloride.htmlPurity :
99.74Solubility :
DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)Smiles :
ClC1=CC2=C(CC(N2)=O)C=C1CCN(CC3)CCN3C4=NSC5=C4C=CC=C5.ClMolecular Formula :
C21H22Cl2N4OSMolecular Weight :
449.40Precautions :
H302, H315, H319, H335References & Citations :
[1]Rollema H, et al. 5-HT (1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48 (3) :229-237.|[2]Schmidt AW, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425 (3) :197-201.|[3]Seeger TF, et al. Ziprasidone (CP-88,059) : a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995;275 (1) :101-113.|[4]Park S, et al. The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012;61 (6) :787-793.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
LaunchedIsoform :
5-HT1 Receptor;5-HT2 Receptor; D2 Receptor; mLAG-3; α-1 microglobulinCAS Number :
[122883-93-6]
